(MIR) Mirion Technologies - Overview
Sector: Industrials | Industry: Specialty Industrial Machinery | Exchange: NYSE (USA) | Market Cap: 4.489m USD | Total Return: -5.6% in 12m
Avg Turnover: 67.8M
EPS Trend: -62.7%
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
P/E ratio 183.5
Share dilution 19.5% YoY
Altman Z'' 0.41 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Mirion Technologies (NYSE: MIR) specializes in radiation detection, measurement, and monitoring solutions through two primary divisions: Medical and Nuclear & Safety. The Medical segment focuses on quality assurance for oncology and diagnostic imaging, while the Nuclear & Safety segment provides instrumentation for reactor control, defense, and laboratory analysis. The company serves a diverse client base ranging from healthcare providers and research laboratories to military organizations and nuclear power plants.
The business model relies on high barriers to entry due to stringent regulatory requirements for radiation safety equipment and the technical complexity of ionizing radiation detection. In the nuclear sector, revenue is often driven by long-term service contracts and the lifecycle requirements of nuclear power plants, which necessitate constant monitoring and decommissioning support. To better understand how these recurring revenue streams impact long-term valuation, you may want to explore the detailed financial breakdowns on ValueRay.
Headquartered in Atlanta, Georgia, Mirion operates internationally across North America, Europe, and the Asia Pacific. The firm transitioned from its original name, Global Monitoring Systems, in 2006 and has since expanded its portfolio to include specialized hardware such as spectroscopy software, imaging cameras for high-radiation environments, and personal dosimetry services for practitioner safety.
- Nuclear energy renaissance drives demand for reactor instrumentation and safety systems
- Medical segment growth accelerates through radiation oncology quality assurance expansion
- Global defense spending increases demand for military radiation detection equipment
- High exposure to government-funded nuclear decommissioning projects impacts long-term revenue
- Regulatory shifts in healthcare imaging safety standards influence medical product adoption
| Net Income: 25.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.67 > 1.0 |
| NWC/Revenue: 62.35% < 20% (prev 37.37%; Δ 24.98% < -1%) |
| CFO/TA 0.04 > 3% & CFO 127.1m > Net Income 25.1m |
| Net Debt (869.2m) to EBITDA (201.3m): 4.32 < 3 |
| Current Ratio: 3.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (244.7m) vs 12m ago 7.82% < -2% |
| Gross Margin: 47.05% > 18% (prev 0.47%; Δ 4.66k% > 0.5%) |
| Asset Turnover: 31.84% > 50% (prev 33.14%; Δ -1.30% > 0%) |
| Interest Coverage Ratio: 1.48 > 6 (EBITDA TTM 201.3m / Interest Expense TTM 38.1m) |
| A: 0.17 (Total Current Assets 890.9m - Total Current Liabilities 279.2m) / Total Assets 3.54b |
| B: -0.15 (Retained Earnings -516.1m / Total Assets 3.54b) |
| C: 0.02 (EBIT TTM 56.2m / Avg Total Assets 3.08b) |
| D: -0.35 (Book Value of Equity -578.7m / Total Liabilities 1.65b) |
| Altman-Z'' = 0.41 = B |
| DSRI: 1.10 (Receivables 280.4m/226.9m, Revenue 981.0m/870.2m) |
| GMI: 1.00 (GM 47.05% / 47.21%) |
| AQI: 0.98 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.13 (Revenue 981.0m / 870.2m) |
| TATA: -0.03 (NI 25.1m - CFO 127.1m) / TA 3.54b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of May 25, 2026, the stock is trading at USD 17.61 with a total of 6,143,934 shares traded.
Over the past week, the price has changed by +0.99%,
over one month by -6.90%,
over three months by -12.83% and
over the past year by -5.61%.
Mirion Technologies has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MIR.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.9 | 58.4% |
P/S = 4.5764
P/B = 2.4422
Revenue TTM = 981.0m USD
EBIT TTM = 56.2m USD
EBITDA TTM = 201.3m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 9.30m USD (from shortTermDebt, last quarter)
Debt = 1.27b USD (from shortLongTermDebtTotal, last quarter) + Leases 33.2m
Net Debt = 869.2m USD (calculated: Debt 1.27b - CCE 397.9m)
Enterprise Value = 5.36b USD (4.49b + Debt 1.27b - CCE 397.9m)
Interest Coverage Ratio = 1.48 (Ebit TTM 56.2m / Interest Expense TTM 38.1m)
EV/FCF = 59.74x (Enterprise Value 5.36b / FCF TTM 89.7m)
FCF Yield = 1.67% (FCF TTM 89.7m / Enterprise Value 5.36b)
FCF Margin = 9.14% (FCF TTM 89.7m / Revenue TTM 981.0m)
Net Margin = 2.56% (Net Income TTM 25.1m / Revenue TTM 981.0m)
Gross Margin = 47.05% ((Revenue TTM 981.0m - Cost of Revenue TTM 519.4m) / Revenue TTM)
Gross Margin QoQ = 46.23% (prev 48.77%)
Tobins Q-Ratio = 1.52 (Enterprise Value 5.36b / Total Assets 3.54b)
Interest Expense / Debt = 3.01% (Interest Expense 38.1m / Debt 1.27b)
Taxrate = 8.87% (2.90m / 32.7m)
NOPAT = 51.2m (EBIT 56.2m * (1 - 8.87%))
Current Ratio = 3.19 (Total Current Assets 890.9m / Total Current Liabilities 279.2m)
Debt / Equity = 0.69 (Debt 1.27b / totalStockholderEquity, last quarter 1.84b)
Debt / EBITDA = 4.32 (Net Debt 869.2m / EBITDA 201.3m)
Debt / FCF = 9.69 (Net Debt 869.2m / FCF TTM 89.7m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.81% (Net Income 25.1m / Total Assets 3.54b)
RoE = 1.11% (Net Income TTM 25.1m / Total Stockholder Equity 2.27b)
RoCE = 1.62% (EBIT 56.2m / Capital Employed (Equity 2.27b + L.T.Debt 1.20b))
RoIC = 1.57% (NOPAT 51.2m / Invested Capital 3.27b)
WACC = 10.23% (E(4.49b)/V(5.76b) * Re(12.34%) + D(1.27b)/V(5.76b) * Rd(3.01%) * (1-Tc(0.09)))
Discount Rate = 12.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 9.68%
[DCF] Terminal Value 70.12% ; FCFF base≈87.5m ; Y1≈92.6m ; Y5≈109.0m
[DCF] Fair Price = 1.63 (EV 1.27b - Net Debt 869.2m = Equity 398.4m / Shares 244.7m; r=10.23% [WACC]; 5y FCF grow 6.53% → 2.50% )
EPS Correlation: -62.74 | EPS CAGR: -14.30% | SUE: 0.32 | # QB: 0
Revenue Correlation: 98.53 | Revenue CAGR: 8.38% | SUE: 3.17 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-16.45% | Revisions=-60% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.12 | Chg30d=-1.20% | Revisions=-43% | Analysts=8
EPS current Year (2026-12-31): EPS=0.54 | Chg30d=-1.91% | Revisions=-40% | GrowthEPS=+17.0% | GrowthRev=+23.0%
EPS next Year (2027-12-31): EPS=0.65 | Chg30d=-2.30% | Revisions=-33% | GrowthEPS=+21.5% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: -60%